tradingkey.logo


tradingkey.logo


Perrigo Company PLC

PRGO
9.519USD
-0.171-1.77%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
887.05MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Perrigo Company PLC āļšāļĢāļīāļĐāļąāļ—

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

āļ‚āđ‰āļ­āļĄāļđāļĨ Perrigo Company PLC


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™PRGO
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Perrigo Company PLC
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 17, 1991
āļ‹āļĩāļ­āļĩāđ‚āļ­Lockwood-Taylor (Patrick)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™8379
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Dec 17
āļ—āļĩāđˆāļ­āļĒāļđāđˆThe Sharp Building
āđ€āļĄāļ·āļ­āļ‡DUBLIN
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX NASDAQ Basic NYSE
āļ›āļĢāļ°āđ€āļ—āļĻIreland
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒD02 TY74
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ3532696738451
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.perrigo.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™PRGO
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 17, 1991
āļ‹āļĩāļ­āļĩāđ‚āļ­Lockwood-Taylor (Patrick)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Perrigo Company PLC


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
102.14K
+15.98%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
72.94K
+32.89%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
72.17K
+16.46%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
47.94K
+12.51%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
--
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
--
Ms. Adriana (Andi) Karaboutis
Ms. Adriana (Andi) Karaboutis
Independent Director
Independent Director
27.63K
--
Mr. Orlando D. Ashford
Mr. Orlando D. Ashford
Independent Chairman of the Board
Independent Chairman of the Board
22.17K
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
10.56K
--
Ms. Julia M. Brown
Ms. Julia M. Brown
Independent Director
Independent Director
8.03K
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
102.14K
+15.98%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
72.94K
+32.89%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
72.17K
+16.46%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
47.94K
+12.51%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
--
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Upper respiratory
182.00M
17.44%
Pain and sleep-aids
169.20M
16.22%
Skincare and personal hygiene
150.60M
14.43%
Healthy lifestyle
133.80M
12.82%
Digestive health
116.10M
11.13%
āļ­āļ·āđˆāļ™ āđ†
291.60M
27.95%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
635.30M
60.89%
Europe
384.00M
36.81%
All other countries
24.00M
2.30%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Upper respiratory
182.00M
17.44%
Pain and sleep-aids
169.20M
16.22%
Skincare and personal hygiene
150.60M
14.43%
Healthy lifestyle
133.80M
12.82%
Digestive health
116.10M
11.13%
āļ­āļ·āđˆāļ™ āđ†
291.60M
27.95%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 21 āļ.āļž.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 21 āļ.āļž.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
T. Rowe Price Associates, Inc.
12.67%
BlackRock Institutional Trust Company, N.A.
10.92%
The Vanguard Group, Inc.
10.82%
Fuller & Thaler Asset Management Inc.
5.68%
Neuberger Berman, LLC
5.47%
āļ­āļ·āđˆāļ™ āđ†
54.43%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
T. Rowe Price Associates, Inc.
12.67%
BlackRock Institutional Trust Company, N.A.
10.92%
The Vanguard Group, Inc.
10.82%
Fuller & Thaler Asset Management Inc.
5.68%
Neuberger Berman, LLC
5.47%
āļ­āļ·āđˆāļ™ āđ†
54.43%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
65.88%
Investment Advisor/Hedge Fund
34.25%
Hedge Fund
6.91%
Insurance Company
2.60%
Research Firm
2.27%
Sovereign Wealth Fund
2.22%
Pension Fund
1.43%
Individual Investor
0.46%
Bank and Trust
0.41%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 1 āļĄ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 1 āļĄ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
775
146.05M
106.12%
-26.05M
2025Q3
771
148.06M
107.58%
-20.94M
2025Q2
791
145.85M
106.01%
-21.49M
2025Q1
812
142.34M
103.61%
-25.15M
2024Q4
806
140.28M
102.80%
-22.73M
2024Q3
798
138.34M
101.41%
-20.68M
2024Q2
800
136.29M
99.93%
-16.34M
2024Q1
799
135.97M
99.77%
-20.56M
2023Q4
809
135.31M
99.86%
-23.17M
2023Q3
797
133.80M
98.82%
-17.47M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
T. Rowe Price Associates, Inc.
16.79M
12.2%
+2.36M
+16.34%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
11.97M
8.7%
+209.84K
+1.78%
Sep 30, 2025
The Vanguard Group, Inc.
13.82M
10.04%
-144.87K
-1.04%
Sep 30, 2025
Fuller & Thaler Asset Management Inc.
2.00M
1.45%
+2.00M
--
Sep 30, 2025
Neuberger Berman, LLC
5.73M
4.16%
+2.02M
+54.36%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
7.70M
5.59%
+181.83K
+2.42%
Sep 30, 2025
State Street Investment Management (US)
6.90M
5.02%
-437.33K
-5.96%
Sep 30, 2025
Thompson, Siegel & Walmsley LLC
3.63M
2.64%
+1.30M
+56.12%
Sep 30, 2025
Invesco Capital Management LLC
1.80M
1.31%
+378.96K
+26.69%
Sep 30, 2025
Cooke & Bieler, L.P.
3.68M
2.67%
+381.29K
+11.56%
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Sound Equity Dividend Income ETF
3.3%
State Street SPDR S&P Pharmaceuticals ETF
2.44%
Invesco Pharmaceuticals ETF
2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
1.32%
First Trust Health Care Alphadex Fund
1.22%
Invesco S&P MidCap 400 Pure Value ETF
1.19%
Invesco High Yield Equity Dividend Achievers ETF
1.11%
iShares U.S. Pharmaceuticals ETF
1.05%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Sound Equity Dividend Income ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.3%
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.44%
Invesco Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.32%
First Trust Health Care Alphadex Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.22%
Invesco S&P MidCap 400 Pure Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.19%
Invesco High Yield Equity Dividend Achievers ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.11%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.05%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 574.20M USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
Feb 19, 2026
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 24, 2026 going ex on Mar 02, 2026
Mar 02, 2026
Mar 24, 2026
Mar 02, 2026
Oct 29, 2025
PRGO.NB Final Cash Dividend of gross USD 0.29 paid on Dec 16, 2025 going ex on Nov 28, 2025
Nov 28, 2025
Dec 16, 2025
Nov 28, 2025
Jul 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Sep 16, 2025 going ex on Aug 29, 2025
Aug 29, 2025
Sep 16, 2025
Aug 29, 2025
Apr 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Jun 17, 2025 going ex on May 30, 2025
May 30, 2025
Jun 17, 2025
May 30, 2025
Feb 19, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 25, 2025 going ex on Mar 07, 2025
Mar 07, 2025
Mar 25, 2025
Mar 07, 2025
Nov 01, 2024
PRGO.NB Final Cash Dividend of gross USD 0.276 paid on Dec 17, 2024 going ex on Nov 29, 2024
Nov 29, 2024
Dec 17, 2024
Nov 29, 2024
Aug 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Sep 17, 2024 going ex on Aug 30, 2024
Aug 30, 2024
Sep 17, 2024
Aug 30, 2024
May 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Jun 18, 2024 going ex on May 31, 2024
May 31, 2024
Jun 18, 2024
May 31, 2024
Feb 26, 2024
PRGO.NB Interim Cash Dividend of gross USD 1.1 paid on Mar 26, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 26, 2024
Mar 07, 2024
Nov 03, 2023
PRGO.NB Final Cash Dividend of gross USD 0.273 paid on Dec 19, 2023 going ex on Nov 30, 2023
Dec 01, 2023
Dec 19, 2023
Nov 30, 2023
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™